Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
CONTEXT: Despite lacking evidence for its safety and efficacy, antipsychotic cotreatment is common in schizophrenia. OBJECTIVE: To evaluate therapeutic and adverse effects of antipsychotic cotreatment vs monotherapy in schizophrenia. DATA SOURCES: Cochrane Schizophrenia Group register and hand searches of relevant journals/conference proceedings. STUDY SELECTION: Randomized controlled trials comparing antipsychotic monotherapy to cotreatment with a second antipsychotic. DATA EXTRACTION AND ANALYSIS: Two authors independently extracted data. For homogenous dichotomous data, we calculated random effects, relative risk (RR), 95% confidence intervals (CIs), and numbers needed to treat (NNT). For continuous data, weighted mean differences were calculated. RESULTS: In 19 studies (1229 patients) with 28 monotherapy and 19 cotreatment arms, antipsychotic cotreatment was superior to monotherapy regarding 2 a priori defined coprimary outcomes: less study-specific defined inefficacy (N = 22, n = 1202, RR = 0.76, CI = 0.63-0.90, P = .002, NNT = 7, CI = 4-17, P = .0008, I(2) = 78.9%) and all-cause discontinuation (N = 20, n = 1052, RR = 0.65, CI = 0.54-0.78, P < .00001). Results were consistent using Clinical Global Impressions thresholds of less than much (P = .006) and less than minimally (P = .01) improved. Specific psychopathology and adverse event data were insufficient to yield meaningful results. In sensitivity analyses, 5 efficacy moderators emerged: concurrent polypharmacy initiation, clozapine combinations, trial duration >10 weeks, Chinese trials, and second-generation + first-generation antipsychotics. In a meta-regression, similar dose combinations, second-generation + first-generation antipsychotics and concurrent polypharmacy initiation remained significant. CONCLUSIONS: In certain clinical situations, antipsychotic cotreatment may be superior to monotherapy. However, the database is subject to possible publication bias and too heterogeneous to derive firm clinical recommendations, underscoring the need for future research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics
Woods, S. W. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0607 · Cited by 2,050
Charbonneau, D. H. (2005) · Europe PMC (PubMed Central) · Cited by 2,041
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.1 · Cited by 1,348
LEUCHT, S., KANE, J., KISSLING, W., HAMANN, J., ETSCHEL, E., & ENGEL, R. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.04.008 · Cited by 1,226
Self-citationJones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,105
McEvoy, J. P., Lieberman, J. A., Stroup, T. S., Davis, S. M., Meltzer, H. Y., Rosenheck, R. A., Swartz, M. S., Perkins, D. O., Keefe, R. S. E., Davis, C. E., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.600 · Cited by 1,018
Clinical implications of Brief Psychiatric Rating Scale scores
Leucht, S., Kane, J. M., Kissling, W., Hamann, J., Etschel, E., & Engel, R. (2005) · British Journal of Psychiatry · doi:10.1192/bjp.187.4.366 · Cited by 896
Self-citationOne hundred years of schizophrenia: a meta-analysis of the outcome literature
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.10.1409 · Cited by 762
Robinson, D. G., Woerner, M. G., McMeniman, M., Mendelowitz, A., & Bilder, R. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.3.473 · Cited by 590
Lewis, S. W., Barnes, T. R. E., Davies, L., Murray, R. M., Dunn, G., Hayhurst, K. P., Markwick, A., Lloyd, H., & Jones, P. B. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj067 · Cited by 422
Schizophrenia, neuroleptic medication and mortality
Joukamaa, M., Heliövaara, M., Knekt, P., Aromaa, A., Raitasalo, R., & Lehtinen, V. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.188.2.122 · Cited by 395
Electroconvulsive therapy for schizophrenia
Tharyan, P., & Adams, C. E. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000076.pub2 · Cited by 354
Clozapine alone versus clozapine and risperidone with refractory schizophrenia
Honer, W. G., Thornton, A. E., Chen, E. Y. H., Chan, R. C. K., Wong, J. O. Y., Bergmann, A., Falkai, P., Pomarol-Clotet, E., McKenna, P. J., Stip, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053222 · Cited by 277
Waddington, J. L., Youssef, H. A., & Kinsella, A. (1998) · British Journal of Psychiatry · doi:10.1192/bjp.173.4.325 · Cited by 267
Shiloh, R., Zemishlany, Z., Aizenberg, D., Radwan, M., Schwartz, B., Dorfman-Etrog, P., Modai, I., Khaikin, M., & Weizman, A. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.171.6.569 · Cited by 260
Freudenreich, O., & Goff, D. C. (2002) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2002.01331.x · Cited by 259
Does antipsychotic polypharmacy increase the risk for metabolic syndrome?
Correll, C. U., Frederickson, A. M., Kane, J. M., & Manu, P. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2006.08.017 · Cited by 252
Self-citationAuquier, P., Lançon, C., Rouillon, F., Lader, M., & Holmes, C. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1325 · Cited by 249
The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia: 2003 Update
Miller, A. L., Hall, C. S., Buchanan, R. W., Buckley, P. F., Chiles, J. A., Conley, R. R., Crismon, M. L., Ereshefsky, L., Essock, S. M., Finnerty, M., et al. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0408 · Cited by 234
Josiassen, R. C., Joseph, A., Kohegyi, E., Stokes, S., Dadvand, M., Paing, W. W., & Shaughnessy, R. A. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.130 · Cited by 233
Ganguly, R., Kotzan, J. A., Miller, L. S., Kennedy, K., & Martin, B. C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1013 · Cited by 227
Clozapine in treatment-resistant schizophrenics.
Kane, J. M., Honigfeld, G., Singer, J., & Meltzer, H. Y. (1988) · PubMed · Cited by 217
Self-citationCarbamazepine for schizophrenia and schizoaffective psychoses
Leucht, S., McGrath, J., White, P., & Kissling, W. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001258 · Cited by 190
Self-citationClark, R. E., Bartels, S. J., Mellman, T. A., & Peacock, W. J. (2002) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006928 · Cited by 189
Yagcioglu, A. E. A., Akdede, B. B. K., Turgut, T. I., Tümüklü, M., Yazici, M. K., Alptekin, K., Ertugrul, A., Jayathilake, K., Gögüs, A., Tunca, Z., et al. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0109 · Cited by 185
Faries, D., Ascher-Svanum, H., Zhu, B., Correll, C., & Kane, J. (2005) · BMC Psychiatry · doi:10.1186/1471-244x-5-26 · Cited by 184
Self-citationCombination Antipsychotic Therapy in Clinical Practice
Tapp, A., Wood, A. E., Secrest, L., Erdmann, J., Cubberley, L., & Kilzieh, N. (2003) · Psychiatric Services · doi:10.1176/appi.ps.54.1.55 · Cited by 181
Benzodiazepines for schizophrenia
Dold, M., Li, C., Tardy, M., Khorsand, V., Gillies, D., & Leucht, S. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006391.pub2 · Cited by 169
Self-citationEarly Prediction of Antipsychotic Response in Schizophrenia
Correll, C. U., Malhotra, A. K., Kaushik, S., McMeniman, M., & Kane, J. M. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.11.2063 · Cited by 169
Self-citationLeucht, S., Helfer, B., Dold, M., Kissling, W., & McGrath, J. J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003834.pub3 · Cited by 163
Self-citationEarly Prediction of Antipsychotic Nonresponse Among Patients With Schizophrenia
Leucht, S., Busch, R. M., Kissling, W., & Kane, J. M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0301 · Cited by 143
Self-citationHenderson, D. C., Kunkel, L., Nguyen, D. D., Borba, C. P., Daley, T. B., Louie, P. M., Freudenreich, O., Cather, C., Evins, A. E., & Goff, D. C. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2005.00612.x · Cited by 114
Citrome, L., Jaffe, A., Levine, J., Allingham, B., & Robinson, J. (2004) · Psychiatric Services · doi:10.1176/appi.ps.55.9.1006 · Cited by 111
Freudenreich, O., Henderson, D. C., Walsh, J. P., Maravić, M. C., & GOFF, D. C. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2006.12.030 · Cited by 106
Glutamatergic drugs for schizophrenia
Tiihonen, J., & Wahlbeck, K. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003730.pub2 · Cited by 106
Paton, C., Whittington, C. J., & Barnes, T. R. E. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318036bfbb · Cited by 101
Antidepressants for the negative symptoms of schizophrenia
Rummel‐Kluge, C., Kissling, W., & Leucht, S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005581.pub2 · Cited by 95
Self-citationLong-term combination antipsychotic treatment in VA patients with schizophrenia
Kreyenbuhl, J. A., Valenstein, M. M., McCarthy, J. F., Ganoczy, D. A., & Blow, F. C. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.02.023 · Cited by 84
Antipsychotic polypharmacy: evidence based or eminence based?
Stahl, S. M. (2002) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2002.2e011.x · Cited by 84
Clozapine in China: a review and preview of US/PRC collaboration
Potter, W. Z., Ko, G. N., Zhang, L. D., et al. (1989) · Psychopharmacology · doi:10.1007/bf00442568 · Cited by 82
Herberg, L. J., & Rose, I. C. (1989) · Psychopharmacology · doi:10.1007/bf00634458 · Cited by 80
Benzodiazepines for schizophrenia
Volz, A., Khorsand, V., Gillies, D., & Leucht, S. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006391 · Cited by 80
Self-citationBasan, A., Kissling, W., & Leucht, S. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.01.016 · Cited by 66
Self-citationCOX-2 Inhibitors as Adjunctive Therapy in Schizophrenia: Rationale for Use and Evidence to Date
Riedel, M. J., Strassnig, M., Schwarz, M., & ller, N. M. ⁄. (2005) · CNS Drugs · doi:10.2165/00023210-200519100-00001 · Cited by 47
Leucht, S., McGrath, J. J., & Kissling, W. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003834 · Cited by 23
Self-citation
Cited by
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Antipsychotic medication in schizophrenia: a review
Lally, J., & MacCabe, J. H. (2015) · British Medical Bulletin · doi:10.1093/bmb/ldv017 · Cited by 513
Barnes, T. R., & the Schizophrenia Consensus Group of the British Association for Psychopharmacology (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 356
Petrides, G., Malur, C., Braga, R. J., Bailine, S. H., Schooler, N. R., Malhotra, A. K., Kane, J. M., Sanghani, S., Goldberg, T. E., John, M., et al. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13060787 · Cited by 352
Self-citation
Metadata
- Authors
- Correll, C. U., Rummel-Kluge, C., Corves, C., Kane, J. M., & Leucht, S.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-04-15
- Volume
- 35
- Issue
- 2
- Pages
- 443-457
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2107625293
- Cited by
- 397
- References
- 50
- FWCI
- 3.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.